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AbsTrACT
background and purpose The optimal time to start 
oral anticoagulant (Oac) in patients with ischaemic 
stroke due to non-valvular atrial fibrillation (aF) is 
unknown. We reviewed Oac timing in relation to 
90-day clinical outcomes as a post hoc analysis from a 
prospective multicentre observational study.
Methods We included patients with data on time to 
initiation of Oac from cROMIs-2 (clinical Relevence Of 
Microbleeds In stroke-2), a prospective observational 
inception cohort study of 1490 patients with ischaemic 
stroke or transient ischaemic attack (TIa) and aF treated 
with Oac. The primary outcome was the composite 
outcome of TIa, stroke (ischaemic stroke or intracranial 
haemorrhage) or death within 90 days of the qualifying 
stroke or TIa. We performed adjusted logistic regression 
analyses to compare early (0–4 days) and later (≥5 days 
or never started) Oac initiation.
results We included 1355 patients, mean age 76 (sD 
10), 580 (43%) women. Oac was started early in 358 
(26%) patients and later (or not at all) in 997 (74%) 
patients. The event rate within 90 days was 48/997 (5%) 
in the late-Oac group (2 intracranial haemorrhages, 18 
ischaemic strokes or TIas and 31 deaths (three deaths 
were as a result of new ischaemic strokes)) versus 7/358 
(2%) in the early-Oac group (5 ischaemic strokes or TIas 
and 2 deaths). In adjusted analyses, late Oac was not 
associated with the composite outcome (adjusted OR 
1.17, 95% cI 0.48 to 2.84, p=0.736).
Conclusion In adjusted analyses, early Oac after 
acute ischaemic stroke or TIa associated with aF was 
not associated with a difference in the rate of the 
composite outcome of stroke, TIa or death at 90 days, 
compared with late Oac. however, despite adjustment 
for important baseline factors, patients selected for early 
Oac and late Oac might still have differed in important 
respects; evaluation of Oac timing in adequately 
powered  randomised trials is required.
Clinical trial registration NcT02513316.
InTroduCTIon
Oral anticoagulation (OAC) is recommended for 
the secondary prevention of ischaemic stroke due 
to non-valvular atrial fibrillation (AF),1 2 but the 
optimal timing of OAC following an acute isch-
aemic stroke or transient ischaemic attack (TIA) is 
unknown.3 4 In AF-related acute ischaemic stroke, 
the risk of early recurrence (within 7–14 days) is 
between 0.4% and 1.3% per day.5–9 AF-related isch-
aemic strokes are more often disabling or fatal than 
other types, with longer hospital stays and higher 
costs,10 so preventing early recurrence is a key clin-
ical challenge. OAC is highly effective for long-term 
stroke prevention in AF,11 but the safety and net 
benefit in acute AF-related stroke have not been 
established.
Initiation of OAC in the first few days after 
stroke could prevent ischaemic stroke recurrence 
but might increase the risk of symptomatic intracra-
nial haemorrhage (ICH), including haemorrhagic 
transformation of the infarct (estimated at ~9% 
in the first 7 days),12 leading to clinical uncertainty 
about when to start OAC. Recent observational 
studies (mostly including patients treated with 
warfarin or other vitamin K antagonists) reported 
an 8%–10% risk of recurrent ischaemic stroke and 
a 2%–4% risk of symptomatic ICH within 90 days 
of AF-related ischaemic stroke.13 14 Current guide-
lines do not provide clear recommendations on the 
timing of OAC after acute AF-related stroke: US 
guidelines suggest that commencing OAC within 14 
days is reasonable.15 The 14-day time delay is likely 
in part derived from the European Atrial Fibrilla-
tion Trial where the time to anticoagulation was 
within 14 days in only 43% of patients,16 as well 
as observational CT-based data suggesting that most 
haemorrhagic transformation occurs within 14 days 
of an ischaemic stroke.17 The European Society of 
Cardiology guidelines recommend starting OAC 
according to infarct size at 1, 3, 6 or 12 days based 
only on expert consensus.18 Current UK guidelines 
for OAC state that ‘delay for an arbitrary 2 week 
period is recommended’ for ‘disabling’ stroke and 
that OAC can be started ‘no later than 14 days’ 
for other strokes, at the prescriber’s discretion (see 
https://www. strokeaudit. org). Indeed, recent trials 
of non-vitamin K oral anticoagulants (direct oral 
anticoagulants, DOACs) excluded patients who 
were started on a DOAC within 7–14, and up to 
30, days of their ischaemic event.19–21
There have been a number of recent retrospective 
and observational studies exploring early OAC use 
in acute stroke (especially with DOACs) suggesting 
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Figure 1 Flow chart of patient inclusion. Oac, oral anticoagulant.
that early OAC is not associated with high rates of stroke events 
or death,13 14 22–26 and there are ongoing randomised control 
trials which aim to explore the safety and efficacy of early OAC 
in ischaemic stroke.27–29
In the present study, we describe the timing of OAC use in a 
prospective multicentre inception cohort observational study 
of adult patients presenting with acute ischaemic stroke or TIA 
and either known or new-onset AF, for which OAC was to be 
started. We reviewed the clinical and radiological character-
istics of patients treated with early (0 to 4 days) versus late 
(5 to 90 days) OAC initiation, and their subsequent clinical 
outcomes.
MATerIAls And MeThods
Participants were recruited as part of the Clinical Relevence Of 
Microbleeds In Stroke-2 study (CROMIS-2), the protocol for 
which has been described elsewhere,30 but briefly CROMIS-2 is 
a multicentre, prospective inception observational study investi-
gating whether cerebral microbleeds and other imaging markers 
of small vessel disease increase the risk of subsequent intracra-
nial haemorrhage in patients with recent stroke and concurrent 
AF treated with anticoagulation. Patients were recruited from 
79 hospitals throughout the UK and one hospital in the Neth-
erlands. Patients were included if they presented with an isch-
aemic stroke or TIA, had AF and were judged by their treating 
physician as suitable for OAC. Patients were excluded if they 
had previously been exposed to OAC. Patients were included 
in this substudy if accurate information on the timing of OAC 
administration was available. The primary outcome was defined 
as a composite first of ischaemic stroke, TIA, ICH or death due 
to any cause within 90 days of the qualifying ischaemic event. 
Patients who had multiple events were not double counted when 
considering our composite event. Subsequent analyses were then 
performed individually for ischaemic events (ischaemic stroke 
and TIA), ICH and mortality. All stroke events required a clinical 
history suggestive of a vascular event with supporting neurora-
diology and were independently adjudicated by DW (Clinical 
Research Fellow) and DJW (Professor of Clinical Neurology) 
blinded to timing of OAC.
Timing of OAC following the index ischaemic event was 
dichotomised into early (4 days or earlier) and late (5 days and 
onwards or anticoagulation never started) based on evidence 
showing that early (≤4 days) might be safe.31 Patients in which 
the exact date of anticoagulation was unknown were excluded 
from the analysis.
Baseline clinical and demographic variables and imaging find-
ings relating to the qualifying event were visually compared 
between the early and late groups. Groups were compared using 
the Mann-Whitney U test if not normally distributed and the 
t-test if normally distributed; categorical variables between the 
groups were compared with the χ2 test or, when appropriate, 
Fisher’s exact test. Imaging studies from the qualifying stroke 
were rated for whether the index lesion fulfilled criteria for 
small vessel occlusion (defined as single small <15 mm Diffusion 
Weighted Imaging (DWI) infarctions within the middle cerebral 
artery distribution or the pons) and for infarct size (defined as 
greater or less than one-third of a vascular territory). Imaging 
was also rated for haemorrhagic transformation using the Euro-
pean Cooperative Acute Stroke Study (ECASS) criteria.32 Cere-
bral microbleeds and white matter hyperintensities (WMHs) 
were rated using validated scales.33 34 WMHs were rated using 
the Fazekas scale; a score of 2 or above in either a periventricular 
or deep white matter region was considered moderate to severe.
We undertook bivariable analyses of our baseline variables 
to decide whether to include each variable in the multivariable 
model. We first fitted the logistic regression model with antico-
agulant timing as the only variable in the model and recorded the 
estimated regression coefficient. Then, one at a time, we adjusted 
for potential confounder variables and recorded whether there 
was a ‘clinically significant’ change (defined as a 10% absolute 
change or more) in the coefficient for timing. If there was, this 
variable was selected for the multivariable model. A multivari-
able logistic regression model was undertaken comparing early 
versus late anticoagulation for our composite outcome and each 
component of the composite outcome. ORs are interpreted as 
risk ratios as the outcome was relatively rare.
Sensitivity analyses were also completed in order to compare 
those with early (0 to 4 days), later (5 to 14 days) and late (15 
days or later or not started at all) OAC start timings. Lastly, 
an exploratory analysis was undertaken excluding patients 
with TIAs and minor stroke (defined as National Institute 
of Health Stroke Score (NIHSS) <2) in whom early OAC is 
recommended.
resulTs
There were 1355 patients with a known OAC start date (figure 1), 
of whom only 54 did not start an OAC. Our cohort was similar 
in baseline demographics and risk factor profile to patients in 
whom the timing of anticoagulation initiation was not known 
(n=135) (data not shown). The mean age was 76 years (SD 10) 
and 570 (43%) were women. The median NIHSS was 4 (IQR 
2–10). A total of 235 (18%) patients had infarcts involving more 
than one-third of a vascular territory while 98 (8%) had lesions 
consistent with small vessel occlusion (table 1). The median time 
to OAC was 11 days (IQR 4–17); 839 (62%) had been started on 
OAC by day 15. Three hundred fifty-eight patients (26%) were 
started on OAC 4 days or earlier after their index stroke. Four 
hundred seventy-five patients (35%) were started on DOACs, 
and the remainder were started on warfarin; .
Comparison of baseline characteristics and risk factors 
(table 1) showed that those who were started early were more 
likely to have been started on a DOAC (46% vs 35%) and less 
likely to have received intravenous thrombolysis (12% vs 22%), 
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Table 1 Demographics and risk factors between those anticoagulated early and late
Variable All (n=1355) Anticoagulated early (n=358)
Anticoagulated late or not at all 
(n=997)
Age, mean (SD) 76 (10) 75 (11) 76 (10)
Sex, female, n (%) 580 (43) 147 (41) 433 (43)
Hypertension, n (%) 846 (63) 211 (59) 635 (65)
Diabetes mellitus, n (%) 222 (16) 54 (15) 168 (17)
Hyperlipidaemia, n (%) 597 (45) 156 (44) 441 (45)
NIHSS, median (IQR)* 4 (2–10) 2 (1–4) 6 (3–11)
Previous stroke/TIA, n (%) 277 (21) 77 (22) 200 (20)
Previous ICH, n (%) 13 (1.0) 1 (0.28) 12 (1.22)
Antiplatelet therapy prior to qualifying stroke, n (%) 703 (52) 198 (55) 505 (51)
Known cognitive impairment or dementia, n (%) 32 (3) 9 (3) 23 (3)
Premorbid mRS, median (IQR) 1 (1–3) 1 (0–2) 2 (1–3)
Dependent living prior to stroke, n (%) 144 (12) 12 (4) 132 (16)
Thrombolysis, n (%) 263 (19) 43 (12) 220 (22)
Bridging heparin, n (%) 324 (24) 93 (26) 231 (23)
CHA2DS2-VASc score, median (IQR) 5 (4–6) 5 (4–6) 5 (4–6)
Qualifying ischaemic stroke >1/3 territory, n (%) 242 (18) 22 (6) 220 (22)
Qualifying ischaemic stroke lacunar, n (%) 98 (8) 28 (8) 70 (8)
PH1 Haemorrhagic transformation, n (%) 17 (1.3) 0 (0%) 17 (1.8)
DOAC on discharge, n (%) 475 (37) 164 (46) 311 (34)
Statin on discharge, n (%) 1043 (79) 266 (75) 777 (81)
Antiplatelet on discharge 717 (53) 114 (32) 603 (60)
Cerebral microbleed presence, n (%) 269 (21) 74 (21) 195 (21)
Moderate to severe WMH, n (%) 368 (29) 93 (26) 275 (30)
*Available in 851 of 1080 (79%) of patients with non-minor ischaemic stroke.
DOAC, direct oral anticoagulant; ICH, intracranial haemorrhage; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Score; PH1, parenchymal haemorrhage 
type 1; TIA, transient ischaemic attack; WMH, white matter hyperintensity.
Table 2 Multivariable model showing the odds of the composite 
outcome (TIA, stroke or death) within 90 days
Variable units or (95% CI) P values
Anticoagulant timing Early Reference
Late 1.17 (0.48 to 2.84) 0.736
Premorbid mRS Per point 1.48 (1.16 to 1.90) 0.002
CHA2DS2VASC Per point 1.21 (0.92 to 1.58) 0.169
DOAC medication on discharge VKA Reference
DOAC 1.29 (0.64 to 2.59) 0.475
DOAC, direct oral anticoagulant; mRS, modified Rankin Scale; TIA, transient 
ischaemic attack; VKA, vitamin K agonist.
have a large infarct (6% vs 22% involving more than one-third 
of a vascular territory) or have significant haemorrhagic trans-
formation (defined as parenchymal haemorrhage type 1 (PH1) 
or above) of the index infarct on MRI (0% vs 1.8%). Those anti-
coagulated early also had less severe strokes (median NHISS 2 vs 
6) and lower pre-stroke functional disability (pre-stroke modi-
fied Rankin Scale (mRS) 1 vs 2), less dependent living (mRS >3) 
(4% vs 16%) and less likely to have had a previous ICH (0.28 
vs 1.22%). Imaging markers of small vessel disease and previous 
antiplatelet use prior to index stroke were similar between the 
early and late OAC groups (55% vs 51%). However, patients 
who started OAC late were more likely to be on antiplatelet 
therapy at discharge from hospital (60% vs 32%) and at 6 
months (although outside of the study follow-up window) (11% 
vs 4%, compared with those who started OAC early). Statin use 
at discharge was similar between the early and late groups (75% 
and 81%, respectively).
Ninety-day follow-up was available in all patients. Overall, 55 
patients had at least one event within 90 days (event rate 4.1%). 
The median time to ischaemic stroke was 14 days (IQR 7–39) 
whereas the median time to ICH was 72 days (IQR 62–82). The 
event rate was 48/997 (5%) in the late-OAC group (two ICHs, 
16 ischaemic strokes (all cardioembolic), two TIAs and 31 deaths 
(three deaths due to new ischaemic strokes)) versus 7/358 (2%) 
in the early-OAC group (three ischaemic strokes (all cardioem-
bolic), two TIAs and two deaths). Of the 33 total deaths, 13 were 
vascular (three new ischaemic strokes, four myocardial infarc-
tions, three instances of heart failure, one instance of gangrene 
and two patients who deteriorated after their original stroke), 
11 were non-vascular and 9 were of unknown cause. In univari-
able analysis, patients starting OAC late were 2.5 times more 
likely to experience the composite outcome than patients who 
started OAC early (OR 2.54, 95% CI 1.14 to 5.66). Bivariable 
analysis showed that premorbid mRS, CHA2DS2VASC score and 
DOAC use were potential confounders, so these were included 
in multivariable analysis. After adjusting for all the potential 
confounders, multivariable analysis showed little evidence for a 
difference in composite outcome according to timing of OAC 
(late OAC OR 1.17, 95% CI 0.48 to 2.84) (table 2). Backwards 
stepwise regression revealed premorbid mRS (OR 1.48; 95% CI 
1.16 to 1.90) to be the most strongly related with outcome and 
the major determinant of change in OR.
Exploring components of the composite outcome in multivari-
able analysis (after running bivariable analysis for each outcome) 
showed no evidence of a difference between early and late OAC 
for risk of ischaemic stroke or TIA  (OR starting late OAC 1.25, 
95% CI 0.36 to 4.41) (table 3), or death (OR starting late OAC 
0.91, 95% CI 0.20 to 4.60) (table 4). There was no evidence for 
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Table 3 Multivariable model showing the odds of recurrent 
ischaemic stroke or TIA within 90 days
Variable units or (95% CI) P values
Anticoagulant timing Early Reference 0.727
Late 1.25 (0.36 to 4.41)
Intravenous thrombolysis No Reference 0.399
Yes 0.48 (0.09 to 2.63)
NIHSS Per point 0.97 (0.85 to 1.11) 0.693
Premorbid mRS Per point 0.84 (0.52 to 1.36) 0.470
Age, CHA2DS2VASC and infarction size were also idenfified as potential 
confounders. Due to the small number of events and a relative smaller effect 
size on the timing coefficient, these were not entered into the model to avoid 
overfitting.
NIHSS, National Institute of Health Stroke Scale; mRS, modified Rankin Scale.
Table 4 Multivariable model showing the odds of death within 90 
days
Variable units or (95% CI) P values
Anticoagulant timing Early Reference
Late 0.91 (0.20 to 4.60) 0.907
CHA2DS2VASC Per point 1.14 (0.75 to 1.75) 0.544
Premorbid mRS Per point 3.69 (2.22 to 6.14) <0.001
DOAC medication on discharge VKA Reference
DOAC 1.42 (0.48 to 4.16) 0.527
DOAC, direct oral anticoagulant; VKA, vitamin K agonist.
a difference in risk of ICH (but with too few events to undertake 
logistic regression (0 vs 0.2%), Fisher’s exact test: p=1.00).
Twenty-two out of 242 (9%) patients with large territorial 
infarctions were started on OAC early; none of these patients 
died or had an ICH within 90 days, but one had a recurrent 
ischaemic stroke. Haemorrhagic transformation was identi-
fied in 203 patients on their baseline MRI scans (which all 
included T2* Gradient Recalled Echo (GRE) blood-sensitive 
sequences). Using the ECASS criteria,32 102 cases were HI1, 
84 were HI2 and 17 were PH1. There were no instances of 
PH2. PH1 was more common in the later OAC group (0% vs 
1.8%, p=0.005). There was no statistical difference between 
HI2 (36% vs 41% p=0.785) or  HI1 (64% vs 50% p=0.388) 
between the early and late OAC groups
Multivariable sensitivity analyses comparing  later (5 to 14 
days) (n=481) and very late OAC (≥15 days or not started at all) 
(n=516) to early OAC (0 to 4 days) (n=358) show little differ-
ence in the odds of our primary composite outcome for these 
groups: starting late, OR 1.19(95% CI 0.45 to 3.90); starting 
very late, OR 1.14 (95% CI 0.42 to 3.09).
In an exploratory analysis of 1080 participants, excluding 
patients with TIA and minor stroke (n=275), 43 individual 
patients had 45 events within 90 days (event rate 4.2% within 
90 days): 14 ischaemic strokes, 2 ICHs and 29 deaths. There was 
little evidence to suggest a difference in our primary composite 
outcome for the late and early OAC groups (late vs early OAC 
OR 0.72; 95% CI 0.19 to 2.73, p=0.630).
dIsCussIon
We show that current practice regarding timing of OAC in 
patients with stroke due to AF varies widely but broadly reflects 
the current guideline considerations and reasonable clinical 
judgement. Just over 25% of our patients were started on OAC 
by 4 days. Patients started on early OAC had milder strokes 
(less severe and of smaller size), were less likely to have been 
thrombolysed and had better pre-stroke functioning (as defined 
by mRS). In adjusted analyses, patients started on early OAC 
had similar odds for the composite end point of intracerebral 
haemorrhage, ischaemic stroke and death compared with those 
started later.
Our findings are consistent with other recent studies in which 
early OAC (variably defined as either <4 days,31 4–14 days13 
or <7 days22) was associated with low event rates of ischaemic 
stroke, ICH and death.13 22 31 While our event rate was much 
lower than those previously reported for the RAF study13 (12.6% 
at 90 days) and VISTA pooled trials analysis14 (13% at 90 days), 
it was similar to a DOAC cohort from Switzerland (7 events in 
204 patients (3.4%); median time to event 28 days). The low 
rate of ischaemic stroke is perhaps in keeping with the expected 
rates extrapolated from the median CHA2DS2-VASc score, while 
the low ICH rate might be because of the high proportion of 
patients treated with DOACs, which are known to have about 
half the risk of ICH as VKAs.2 Similar to the Swiss cohort, 
CROMIS-2 selected patients who were MRI tolerant, an inclu-
sion criteria not used  in the RAF or VISTA trials, which may 
also go some way to explaining the lower event rates we found.
Our study confirms the wide UK variation in the timing of 
OAC administration after ischaemic stroke or TIA in patients 
with AF, possibly reflecting clinician uncertainty and ambiguity 
in available guidelines. In our study, of those anticoagulated, 
34% were anticoagulated after day 14 and 17% after day 20. 
We did not collect information on why these patients had their 
OAC substantially delayed. Although PH1 was over-represented 
in patients anticoagulated late, it only accounted for 17 of 997 
(2%) patients and so is unlikely to be the sole cause for the delay 
in OAC in the majority of these patients. It is possible that some 
of these delays were due to logistical reasons, for example as a 
consequence of communication or transfer of care at discharge, 
though we could not measure this. Starting OAC early (within 
4 days) could therefore have an important practical  advantage 
because the responsibility for initiating OAC would be taken 
by the acute stroke team, making logistical and communication 
challenges much less likely.
Our logistic models should be interpreted with caution and 
should not be used to guide clinical decisions. Death by 90 
days was the main cause of difference in event rates between 
those starting OAC early versus those who started late in our 
composite outcome, and is nearly fully accounted for by the 
addition of premorbid mRS into a multivariable model. In this 
observational study, commencement of OAC was deferred in the 
face of more severe stroke and more severe comorbidity, so late 
OAC might be expected to be associated with higher mortality. 
Moreover, most of the deaths were due to non-vascular causes 
so might not be related to OAC timing. Our results, showing no 
evidence of hazard from early OAC, should nevertheless help 
inform future randomised control trials.
Strengths of our study include its multicentre design, making 
our results reflective of current UK practice. In our multivariable 
analysis, we adjusted for stroke severity and infarct size as well as 
CHA2DS2-VASc and estimated pre-stroke mRS, the major differ-
ences between the two groups. The main limitation of the study 
is its observational nature, where unmeasured treatment biases 
are impossible to adjust for, including clinician characteristics 
and patient frailty. Further markers of patient frailty, such as ‘do 
not rescuscitate’ orders, were not available. The low number of 
events within 90 days, specifically intracerebral events, precludes 
any further investigation into predictors of early haemorrhage. 
As stroke to MRI time was not standardised, more detained 
assessment of baseline infarct volume was not possible. A 
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standardised MRI imaging time with assessment of DWI lesion 
volumes would be preferable.
Lastly, patients had to tolerate an MRI brain to be enrolled in 
CROMIS-2, which is likely to have led to the exclusion of older 
patients with more severe strokes, contributing to the median 
NIHSS of 4. Individuals with severe stroke, HF or unable to 
provide consent personally or via a consultee are likely to have 
a higher risk of events during the first 3 months, but were 
not included. Our findings are therefore only generalisable to 
patients with mild to moderately severe stroke who can undergo 
brain MRI.
Nevertheless, our data suggest that starting OAC early after 
ischaemic stroke is associated with low event rates of recurrent 
ischaemic stroke, ICH and death in selected patients, but the 
benefits and risks need to be tested in randomised trials over 
a full range of stroke severities. While we found a moderate 
(non-significant) effect size, the rarity of early events might 
require large sample sizes. We suggest randomised control trials 
should therefore consider similar designs and common clinical 
outcomes to allow for subsequent pooled individual patient data 
meta-analyses.
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